Although statins are established therapy for the secondary prevention of ischemic stroke, factors associated with adherence to statin treatment following ischemic stroke are not well known. To address this, we assessed the 6-month statin adherence using 8-item Morisky Medication Adherence Scale-8 in patients with acute ischemic stroke. Of 991 patients, 65.6% were adherent to statin at 6-month after discharge. Multiple logistic regression analysis showed that patients’ awareness of hyperlipidemia (OR 1.62; 95% CI 1.07–2.43), large artery stroke subtype (versus non-large artery stroke, OR 1.79; 95% CI 1.19–2.68), and alcohol drinking habits (OR 1.64; 95% CI 1.06–2.53) were positively associated, while high statin dose (versus low dose, OR 0.6; 95% CI 0.40–0.90) and higher daily number of medication pills (OR 0.93; 95% CI 0.88–0.97) were found to have a negative association with self-reported good adherence to statin medication after acute ischemic stroke. However, stroke severity and diagnosis of hyperlipidemia were not associated with adherence. These results suggest that educational and motivational interventions may enhance statin adherence because modifiable factors were associated with statin adherence.

Keywords:
Acute ischemic stroke, Statin adherence, Patient-reported outcomes, Quality of life
1.
Benjamin EJ, Blaha MJ, Chiuve SE, et al: Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017; 135:e1–e459.
2.
Ko Y, Park JH, Kim WJ, et al: The long-term incidence of recurrent stroke: single hospital-based cohort study. J Korean Neurol Assoc 2009; 27: 110–115.
3.
Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C: Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004; 35: 731–735.
4.
Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM: Lipid levels and the risk of ischemic stroke in women. Neurology 2007; 68: 556–562.
5.
Choi JC, Lee JS, Park TH, et al: Effect of pre-stroke statin use on stroke severity and early functional recovery: a retrospective cohort study. BMC Neurol 2015; 15: 120.
6.
Colivicchi F, Bassi A, Santini M, Caltagirone C: Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38: 2652–2657.
7.
Lee M, Saver JL, Wu YL, et al: Utilization of statins beyond the initial period after stroke and 1-year risk of recurrent stroke. J Am Heart Assoc 2017; 6:e005658.
8.
Ni Chroinin D, Callaly EL, Duggan J, et al: Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke 2011; 42: 1021–1029.
9.
Kopjar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN: Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 2003; 92: 1106–1108.
10.
Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Jama 2002; 288: 462–467.
11.
Aday LA, Cornelius LJ: Designing and Conducting Health Surveys: A Comprehensive Guide, ed 3. San Francisco, Jossey-Bass Publishers, 2006.
12.
Morisky DE, Ang A, Krousel-Wood M, Ward HJ: Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich, Conn) 2008; 10: 348–354.
13.
Lee WY, Ahn J, Kim JH, et al: Reliability and validity of a self-reported measure of medication adherence in patients with type 2 diabetes mellitus in Korea. J Int Med Res 2013; 41: 1098–1110.
14.
Hankey GJ, Jamrozik K, Broadhurst RJ, et al: Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998; 29: 2491–2500.
15.
Baigent C, Keech A, Kearney PM, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England) 2005; 366: 1267–1278.
16.
Amarenco P, Bogousslavsky J, Callahan A 3rd, et al: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–559.
17.
LaRosa JC, Grundy SM, Waters DD, et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.
18.
Stone NJ, Robinson JG, Lichtenstein AH, et al: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889–2934.
19.
Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005; 353: 487–497.
20.
Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–461.
21.
Banach M, Stulc T, Dent R, Toth PP: Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol 2016; 225: 184–196.
22.
Chen PS, Cheng CL, Kao Yang YH, Li YH: Statin adherence after ischemic stroke or transient ischemic attack is associated with clinical outcome. Circ J 2016; 80: 731–737.
23.
Flint AC, Conell C, Ren X, et al: Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation. Stroke 2017; 48: 1788–1794.
24.
Kim J, Lee HS, Nam CM, Heo JH: Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke 2017; 48: 2723–2730.
25.
Chodick G, Shalev V, Gerber Y, et al: Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167–2179.
26.
Degli Esposti L, Saragoni S, Batacchi P, et al: Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther 2012; 34: 190–199.
27.
Glader EL, Sjolander M, Eriksson M, Lundberg M: Persistent use of secondary -preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397–401.
28.
Bushnell CD, Olson DM, Zhao X, et al: Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011; 77: 1182–1190.
29.
Gazmararian JA, Kripalani S, Miller MJ, Echt KV, Ren J, Rask K: Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. J Gen Intern Med 2006; 21: 1215–1221.
30.
Kronish IM, Edmondson D, Goldfinger JZ, Fei K, Horowitz CR: Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks. Stroke 2012; 43: 2192–2197.
31.
Kirkpatrick AC, Vincent AS, Guthery L, Prodan CI: Cognitive impairment is associated with medication non-adherence in asymptomatic carotid stenosis. Am J Med 2014; 127: 1243–1246.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.